Float is about 72 million shares, according to Yahoo, but I believe it is far less in practical terms. I think most large institutions are looking at this stock the same way I do, that is, as a long term investment with tremendous long term potential, and they are probably going to hold on or even accumulate more.
I expect to be holding a considerable position in 5 years. I have never sold any shares and I have been accumulating since November of 2005. This company could follow a similar path of Medimmune which sold in 2007 for $15+ billion. I think we could actually see a company worth more than that in 2014. The RSV and Shingles vaccines should each be block-buster (Billion dollar) vaccines. In addition, there are many other disease targets that Novavax will go after with their VLP platform.
I believe the stock price is much lower than it should be because the stock market is looking at this company the way it values all Biotech companies with a product pipeline, that is, a typical high failure rate of products in clinical trials. Vaccines are different than drugs and have a much more predictable outcome of success. The CEO has stated this same theory in his presentations and obviously Oppie, Wellington, Ironwood, Cadila, KPCB, Prospect, and now ROVI agree.
Bill
News 
Market Data 
Discover 
AI
